CLONAL EVOLUTION IN MYELODYSPLASIA AND ACUTE MYELOID LEUKAEMIA FOLLOWING AZACITIDINE
Grant number: 1128984 | Funding period: 2017 - 2020
The myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) represent a spectrum of clinically heterogeneous malignancies that remain incurable in the vast majority of patients. Whilst the DNA mutations underpinning the initiation/maintenance of these malignancies are largely known we have little insight into how these mutations alter response to therapy. Using a range of sophisticated cutting edge technologies we will study how these DNA mutations evolve over the course of treatment.
Related publications (2)
An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in Cancer
Marian L Burr, Christina E Sparbier, Kah Lok Chan, Yih-Chih Chan, Ariena Kersbergen, Enid YN Lam, Elizabeth Azidis-Yates, Dane Vassiliadis, Charles C Bell, Omer Gilan, Susan Jackson, Lavinia Tan, Stephen Q Wong, Sebastian Hollizeck, Ewa M Michalak, Hannah Siddle, Michael T McCabe, Rab K Prinjha, Glen R Guerra, Benjamin J Solomon
Molecular disease monitoring using circulating tumor DNA in myelodysplastic syndromes
Paul Yeh, Michael Dickinson, Sarah Ftouni, Tane Hunter, Devbarna Sinha, Stephen Q Wong, Rishu Agarwal, Ravikiran Vedururu, Kenneth Doig, Chun Yew Fong, Piers Blombery, David Westerman, Mark A Dawson, Sarah-Jane Dawson